These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 28464039)
81. Non-Association of Driver Alterations in PTEN with Differential Gene Expression and Gene Methylation in IDH1 Wildtype Glioblastomas. Mallik MK; Majumdar K; Mujtaba S Brain Sci; 2023 Jan; 13(2):. PubMed ID: 36831729 [TBL] [Abstract][Full Text] [Related]
82. Antioxidants in brain tumors: current therapeutic significance and future prospects. Qi X; Jha SK; Jha NK; Dewanjee S; Dey A; Deka R; Pritam P; Ramgopal K; Liu W; Hou K Mol Cancer; 2022 Oct; 21(1):204. PubMed ID: 36307808 [TBL] [Abstract][Full Text] [Related]
83. Integrating thousands of PTEN variant activity and abundance measurements reveals variant subgroups and new dominant negatives in cancers. Matreyek KA; Stephany JJ; Ahler E; Fowler DM Genome Med; 2021 Oct; 13(1):165. PubMed ID: 34649609 [TBL] [Abstract][Full Text] [Related]
84. Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments. Rajaratnam V; Islam MM; Yang M; Slaby R; Ramirez HM; Mirza SP Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290213 [TBL] [Abstract][Full Text] [Related]
85. Quality Control Strategy for CRISPR-Cas9-Based Gene Editing Complicated by a Pseudogene. Hanss Z; Boussaad I; Jarazo J; Schwamborn JC; Krüger R Front Genet; 2019; 10():1297. PubMed ID: 31998363 [TBL] [Abstract][Full Text] [Related]
86. AEBP1 down regulation induced cell death pathway depends on PTEN status of glioma cells. Sinha S; Renganathan A; Nagendra PB; Bhat V; Mathew BS; Rao MRS Sci Rep; 2019 Oct; 9(1):14577. PubMed ID: 31601918 [TBL] [Abstract][Full Text] [Related]
87. Detection and Correlation of Single and Concomitant Pessôa IA; Amorim CK; Ferreira WAS; Sagica F; Brito JR; Othman M; Meyer B; Liehr T; de Oliveira EHC Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151164 [TBL] [Abstract][Full Text] [Related]
88. Apoptotic Signaling Pathways in Glioblastoma and Therapeutic Implications. Valdés-Rives SA; Casique-Aguirre D; Germán-Castelán L; Velasco-Velázquez MA; González-Arenas A Biomed Res Int; 2017; 2017():7403747. PubMed ID: 29259986 [TBL] [Abstract][Full Text] [Related]
89. Correction of PTEN mutations in glioblastoma cell lines via AAV-mediated gene editing. Hill VK; Kim JS; James CD; Waldman T PLoS One; 2017; 12(5):e0176683. PubMed ID: 28464039 [TBL] [Abstract][Full Text] [Related]
90. Cell surface area and membrane folding in glioblastoma cell lines differing in PTEN and p53 status. Memmel S; Sukhorukov VL; Höring M; Westerling K; Fiedler V; Katzer A; Krohne G; Flentje M; Djuzenova CS PLoS One; 2014; 9(1):e87052. PubMed ID: 24498019 [TBL] [Abstract][Full Text] [Related]
91. C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells. Guo P; Nie Q; Lan J; Ge J; Qiu Y; Mao Q Biochem Biophys Res Commun; 2013 Nov; 441(1):186-90. PubMed ID: 24140063 [TBL] [Abstract][Full Text] [Related]
92. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Kawaguchi T; Yamashita Y; Kanamori M; Endersby R; Bankiewicz KS; Baker SJ; Bergers G; Pieper RO Cancer Res; 2006 Dec; 66(23):11331-40. PubMed ID: 17145879 [TBL] [Abstract][Full Text] [Related]
93. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Parsa AT; Waldron JS; Panner A; Crane CA; Parney IF; Barry JJ; Cachola KE; Murray JC; Tihan T; Jensen MC; Mischel PS; Stokoe D; Pieper RO Nat Med; 2007 Jan; 13(1):84-8. PubMed ID: 17159987 [TBL] [Abstract][Full Text] [Related]
95. A new class of cancer-associated PTEN mutations defined by membrane translocation defects. Nguyen HN; Yang JM; Rahdar M; Keniry M; Swaney KF; Parsons R; Park BH; Sesaki H; Devreotes PN; Iijima M Oncogene; 2015 Jul; 34(28):3737-43. PubMed ID: 25263454 [TBL] [Abstract][Full Text] [Related]